SCHEMBL588908

SCHEMBL588908

O=S(=O)(Nc1cc(S(=O)(=O)c2ccccc2)c(O)c2ccccc12)c1ccc(Cl)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HKDC1 Q2TB90 4/20 0.60
MCL1 Q07820 3/20 0.60
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
KEAP1 Q14145 2/20 0.60
NFE2L2 Q16236 2/20 0.60
POLB P06746 1/20 0.60
G6PD P11413 1/20 0.60
CFTR P13569 1/20 0.60
FABP4 P15090 1/20 0.60
RAB9A P51151 1/20 0.60
BLM P54132 1/20 0.60
GOPC Q9HD26 1/20 0.60
EP300 Q09472 1/20 0.57
BCL2 P10415 1/20 0.57
BCL2L1 Q07817 1/20 0.57
BCL2A1 Q16548 1/20 0.57
BCL2L2 Q92843 1/20 0.57
TP53 P04637 2/20 0.56
MAPT P10636 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13510382 0.83 EP300 (0.80) HKDC1MCL1MEN1KMT2AKEAP1
SCHEMBL5309797 0.81 EP300 (0.68) HKDC1MCL1MEN1KMT2AKEAP1
SCHEMBL13510376 0.80 EP300 (0.80) HKDC1MCL1MEN1KMT2AKEAP1
SCHEMBL13509686 0.78 MCL1 (0.71) HKDC1MCL1MEN1KMT2AKEAP1
SCHEMBL4954492 0.76 HKDC1 (0.82) HKDC1KMT2AKEAP1NFE2L2EP300
SCHEMBL12032535 0.76 ERBB2 (0.66) MCL1ERBB2HSP90AA1HSP90AB1GAA
SCHEMBL2239169 0.75 MCL1 (1.00) HKDC1MCL1MEN1KMT2AKEAP1
SCHEMBL11301921 0.74 GAA (0.70) HKDC1MCL1MEN1KMT2AKEAP1
SCHEMBL2238773 0.74 MCL1 (0.67) HKDC1MCL1MEN1KMT2AKEAP1
SCHEMBL13509800 0.73 STAT3 (0.76) HKDC1MCL1MEN1KMT2AKEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4208021-A1 PREPARATION OF NUCLEATED RBC (NRBC) ANALOGS FOR USE AS REFERENCE HEMATOLOGY CONTROLS IN AUTOMATED HEMATOLOGY ANALYZERS Bio-Rad Laboratories, Inc. (US) 2023-07-12 EP disclosed
CN-116097093-A Preparation of Nucleated RBC (NRBC) analogs for use as reference blood controls in automated blood analyzers 生物辐射实验室股份有限公司 2023-05-09 CN disclosed
EP-2376908-B1 SIMULATION OF NORMAL FRESH BLOOD PLATELETS BIO RAD LABORATORIES (US) 2014-12-31 EP disclosed
US-8114580-B2 Simulation of normal fresh blood platelets for reference control BIO-RAD LABORATORIES, INC. (US) 2012-02-14 US disclosed
EP-2376908-A1 SIMULATION OF NORMAL FRESH BLOOD PLATELETS Bio-Rad Laboratories, Inc. (US) 2011-10-19 EP disclosed
WO-2010083130-A1 SIMULATION OF NORMAL FRESH BLOOD PLATELETS BIO-RAD LABORATORIES, INC. (US) 2010-07-22 WO disclosed
US-20100178647-A1 SIMULATION OF NORMAL FRESH BLOOD PLATELETS BIO-RAD LABORATORIES, INC. (US) 2010-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100178647-A1 SIMULATION OF NORMAL FRESH BLOOD PLATELETS MPL, THPO, PFKP HKDC1 4363/4885MCL1 66/4885MEN1 906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.